Agilent Technologies Inc

Agilent Technologies Inc (A) Stock Analysis

$172.970

-2.543 (-1.47%)At close

Loading chart…
High
177.470
Open
175.040
VWAP
174.20
Volume
2.90M
Mkt Cap
38.16B
Low
172.160
Amount
505.20M
EV/EBITDA, TTM
22.36

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.

AI analysis of Agilent Technologies Inc (A)

Buy

Agilent Technologies Inc is a good buy right now due to its strong financial performance and positive market outlook. The current price is $170.54, with a forward P/E ratio of 23.87, indicating reasonable valuation for growth. The gross margin has improved to 55.54%, reflecting operational efficiency. Additionally, analysts have set a price target range between $180 and $195, suggesting a potential upside of approximately 5.5% to 14.4%. The main risk is the recent decline in liquid chromatography-mass spectrometry equipment sales, which may affect future revenue growth.

Valuation Metrics

The current forward P/E ratio for Agilent Technologies Inc (A) is 23.87, compared to its 5-year average forward P/E of 23.98.

Forward P/E

Fair
5Y Average P/E
23.98
Current P/E
23.87
Overvalued
27.04
Undervalued
20.92

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
19.70
Current EV/EBITDA
22.36
Overvalued
22.02
Undervalued
17.38

Forward P/S

Fair
5Y Average P/S
5.52
Current P/S
6.20
Overvalued
6.23
Undervalued
4.81

Alphio AI Price Scenarios for A

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%A

$115.77

Scenario price

B

Base

Base · 50%A

$100.17

Scenario price

B

Bear

Bear · 25%A

$81.51

Scenario price

Whales holding A

C

CCLA Investment Management Limited

+ HoldingA

+6.35%

3M Return

T

Troy Asset Management Ltd

+ HoldingA

+6.32%

3M Return

L

LGT Capital Partners Ltd.

+ HoldingA

+4.08%

3M Return

D

Deroy & Devereaux Private Investment Counsel, Inc.

+ HoldingA

+3.51%

3M Return

H

Harvest Portfolios Group Inc.

+ HoldingA

+3.43%

3M Return

C

Candriam, Société En Commandite Par Actions

+ HoldingA

+3.43%

3M Return

Events Timeline

2026-10-01 (ET)

08:30:00

Agilent Launches NovoStation Sample Preparation System

2026-09-29 (ET)

08:30:00

Agilent Launches Gen5 AI Cell Identification Module

2026-09-21 (ET)

08:31:00

Agilent Launches TapeStationDx Systems for Clinical Labs

2026-09-08 (ET)

08:30:00

Agilent Technologies Independent Chair Koh Boon Hwee Retires

News

A FAQ — answered by Alphio AI

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Agilent Technologies Inc is a good buy right now due to its strong financial performance and positive market outlook. The current price is $170.54, with a forward P/E ratio of 23.87, indicating reasonable valuation for growth. The gross margin has improved to 55.54%, reflecting operational efficiency. Additionally, analysts have set a price target range between $180 and $195, suggesting a potential upside of approximately 5.5% to 14.4%. The main risk is the recent decline in liquid chromatography-mass spectrometry equipment sales, which may affect future revenue growth.

Community

More ↗

$BinanceBee Liangxi has issued another token! It's getting more and more like a cash grab. Truly shameless. All the good reputation from before has been used to harvest retail investors.

Show more
Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading